Abstract
Mesoridazine (TPS-23), a derivative of thioridazine, has been tried on twenty male psychotic patients with doses varying from 125 to 600 mg per day for a period of about two months. Modified BPRS and global clinical impression were our basis for evaluation of results. The improvement consisted mainly in a reduction of anxiety and symptoms related to it, particularly affective participation to delusions, also better attitude of the patient to his interviewers and other patients, considering that the most distinct symptoms of schizophrenic dissociation were not affected. Secondary effects were frequent, but moderate; frequency of extra-pyramidal effects impressed us, contrarily to most preceding researches.
N.B.—Among twenty patients treated, ten had been receiving a neuroleptic medication for ten years without noticeable improvement.